Ciletatug vedotin clinical trials
How each study uses ciletatug vedotin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ciletatug vedotin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2021 (1)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ciletatug vedotin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid TumorsRecruitingPhase 1/2RemeGen Co., Ltd.NCT06038396Written as RC118
- A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid TumorsRecruitingPhase 1/2RemeGen Co., Ltd.NCT05205850Written as RC118-ADC
- A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid TumoursCompletedPhase 1RemeGen Co., Ltd.NCT04914117Written as RC118 for injection
Codes
What other systems call ciletatug vedotin · ClinicalTrials.gg INT015465
- UNII (FDA) 7ER98K4WW9CILETATUG VEDOTINOne source FDA
- NCI Thesaurus C180906Ciletatug VedotinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 7ER98K4WW9 | CILETATUG VEDOTIN | One source FDA |
| NCI Thesaurus | C180906 | Ciletatug Vedotin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.